AbbVie-Allergan complete, but critics continue to raise anti-competitive concerns
The Abbvie-Allergan mega-merger may now be complete, but its critics haven’t had their last say.
In a 7-page letter to the Federal Trade Commission …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
